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A randomized, controlled, open-label parallel-group, single-center study to determine biomarkers of
exposure to 12 selected harmful and potentially harmful constituents (HPHC) in cigarette smoke and uri-
nary excretion of mutagenic material in 72 male and female Korean subjects smoking Lark One cigarettes
(1.0 mg tar, 0.1 mg nicotine, and 1.5 mg CO) at baseline. Subjects were randomized to continue smoking
Lark One cigarettes, or switch to an Electrically Heated Cigarette Smoking System (EHCSS) and EHCSS-K3
cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO), or to no-smoking. The mean decreases from baseline
to Day 8 were statistically signiﬁcant (all p < 0.05) for 10 of 12 HPHC in mainstream cigarette smoke
including CO (the primary objective) in the EHCSS-K3 group (range: 1.5% to 74.2%). Exposure to the
other determined HPHC was not signiﬁcantly different. In the Lark One group, the mean exposure to 6
of 12 HPHC in cigarette smoke was signiﬁcantly (all p < 0.05) decreased; however, exposure to CO was
signiﬁcantly increased. The largest mean reductions in biomarkers of exposure to HPHC occurred in
smokers who switched to no-smoking (3.4% to 98.9%). The mean excretion of mutagenic material
was signiﬁcantly decreased (p < 0.05) in the EHCSS-K3 and no-smoking groups (31.8% and 45.3%,
respectively), and increased in the Lark One group (+31.5%).
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
There is overwhelming medical and scientiﬁc consensus that
cigarette smoking causes lung cancer, heart disease, emphysema,
and other serious diseases in smokers (Ha et al., 2003; US Depart-
ment of Health and Human Services, 2010). In the US the Family
Smoking Prevention and Tobacco Control Act (FSPTCA) (Family
Smoking Prevention and Tobacco Control Act, 2009) has empow-
ered the Food and Drug Administration (FDA) to evaluate and reg-
ulate modiﬁed risk tobacco products (MRTPs) (Deyton et al., 2010).
The FDA, in consultation with the Institute of Medicine (IOM), has
also been charged to issue guidance and regulations on the scien-
tiﬁc evidence required for the assessment and ongoing review of
MRTPs (Food and Drug Administration, 2012; Institute of Medicine,
2012).
The Electrically Heated Cigarette Smoking System (EHCSS) re-
duces many of the toxicologically important HPHC present in
mainstream cigarette smoke and signiﬁcantly lowers the biological
activity of the smoke aerosol compared to conventional lit-end
cigarettes in laboratory-based test systems (Werley et al., 2008;
Zenzen et al., 2012). Electrical heating of the tobacco reduces. Tricker).
-NC-ND license.pyrolysis, and produces smoke that contains lower amounts of
most cigarette smoke HPHC. The current third-generation EHCSS
is a puff-activated electrical heater that can only be used to smoke
EHCSS series-K cigarettes, but not conventional lit-end cigarettes.
The current assessment, the second in a series of ﬁve clinical
evaluations describing data from investigations performed under
both controlled and real-life smoking conditions (Martin Leroy
et al., 2012; Tricker et al., 2012a,b,c), reports a randomized, con-
trolled, open-label, parallel-group, single-center study to evaluate
differences in the exposure to selected HPHC in cigarette smoke
and excretion of mutagenic material in urine. Subjects usually
smoking the Lark One non-menthol cigarette (Lark1) at baseline
were randomized to continue smoking the Lark1 cigarette, or
switch to use the EHCSS heater to smoke the EHCSS-K3 cigarette,
or to switch to no-smoking, for a duration of 8 days. The study
was designed to examine changes in selected tobacco-speciﬁc
and tobacco-related biomarkers of exposure to HPHC present both
in the gas–vapor phase (1,3-butadiene, acrolein, benzene, CO, and
crotonaldehyde) and particulate phase (2-naphthylamine, 4-ami-
nobiphenyl, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
[NNK], acrylamide, nicotine, pyrene, and o-toluidine) of main-
stream cigarette smoke, as well as excretion of mutagenic material
in urine.
The primary objective of the study was to assess exposure to
CO, determined as carboxyhemoglobin concentration in blood at
S46 A.R. Tricker et al. / Regulatory Toxicology and Pharmacology 64 (2012) S45–S5317:00 (COHb17:00), between the study groups on Day 8. Exposure to
CO was selected as the primary objective based on the reduction of
CO in mainstream smoke compared to conventional cigarettes
(Werley et al., 2008; Zenzen et al., 2012) and the previous observa-
tion that COHb is reduced in smokers after switching to the EHCSS
(Frost-Pineda et al., 2008a,b).
2. Materials and methods
2.1. Subjects
Adult male and female Korean smokers (aged 20–50) with
acceptable health conditions who smoked 10–30 conventional
lit-end non-menthol cigarettes (1.0–3.0 mg tar) per day and the
Lark1 (1.0 mg tar, 0.1 mg nicotine, and 1.5 mg CO) as their exclu-
sive brand for at least 2 weeks prior to admission to the clinic were
recruited. All enrolled subjects signed an informed consent form
prior to screening procedures. Subjects were compensated for
study participation and were free to withdraw from the study at
any time. Screening was performed within a 2 week prior to study
enrolment and included medical history, physical examination, vi-
tal signs, electrocardiogram (ECG), pulmonary function tests, clin-
ical laboratory, COHb, and the Fagerström Test for Nicotine
Dependence (FTND) (Heatherton et al., 1991). Women of child-
bearing potential who used a reliable method of contraception
were considered as eligible for study inclusion; pregnant or lactat-
ing women were excluded. Other exclusion criteria included exis-
tence of a clinically signiﬁcant disease, clinically relevant abnormal
ﬁndings on physical examination, medical history, and clinical lab-
oratory results, alcohol or drug abuse, and a positive test for hu-
man immunodeﬁciency virus (HIV) or hepatitis. Subjects using a
nicotine-containing product other than cigarettes within 3 months
prior to screening, or having <1.5% COHb saturation (suggestive of
being a non-smoker) were also excluded. The use of any medica-
tion with the exception of hormonal contraceptives for female sub-
jects was prohibited in the week before the study.
2.2. Cigarette products
A leading commercial conventional cigarette (CC) brand (Lark
One) was chosen to represent the Korean cigarette market in which
smokers have a preference for smoking cigarettes with very lowLark1 
 (N = 72) 
Subject 
Recruitment 
and    
medical 
screening 
Cont
Day -1 
Biomarker ass
Fig. 1. Schedule of study events. Footnote: On Day-1 (baseline) all subjects smoked the
described in Table 2.International Organization for Standardization (ISO) tar and nico-
tine yields. Lark1 also has a similar tobacco blend to that used in
the EHCSS test cigarettes. Lark1 was analyzed for tar and nicotine
according to ISO methods. All study cigarettes were conditioned
according to ISO standard 3402 (International Organization for
Standardization, 1991). Lark1 was smoked on a smoking machine
according to ISO standard 3308 (International Organization for
Standardization, 2000a). Tar, nicotine and CO were determined
according to ISO standards 4387, 10315, and 8454, respectively
(International Organization for Standardization, 2000b,c, 1995).
Mainstream smoke from EHCSS cigarettes was generated on a
modiﬁed smoking machine with a carousel adapted to use the
EHCSS series-K lighter. The EHCSS smoke generation conformed
with ISO standard 3308; some slight technical deviations were re-
quired. The ISO yields as declared on the cigarette packaging were
as follows: Lark One (Lark1; 1.0 mg tar, 0.1 mg nicotine, and 1.5 mg
CO) and EHCSS-K3 (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO).2.3. Study design and conduct
Enrolled subjects (N = 99, 75 males and 24 females) completed a
7-day smoking diary prior to check-in on Day -2 (Fig. 1). The med-
ian daily cigarette consumption was used to determine the maxi-
mum number of cigarettes that the subject could smoke during
the in-clinic conﬁnement. On Day -2, subjects entered the clinic
before 08:00. Vital signs and ECG were measured (08:00), clinical
laboratory and a physical examination performed to re-conﬁrm eli-
gibility for study inclusion. All subjects were conﬁned to the clinic
from Day -2 to Day 9 under medical supervision. On Day -1 (base-
line), assessments included determination of biomarkers of expo-
sure in a 24-h urine sample (combined urine voids starting at
07:00), vital signs (07:00), COHb (COHb0700 and COHb17:00; 07:00
and 17:00), plasma cotinine and nicotine (COT-P17:00 and NIC-
P17:00; 17:00). Seventy-two subjects (54 males and 18 females)
were randomized into 1 of 3 parallel groups (Lark1: N = 28;
EHCSS-K3: N = 28; and no-smoking: N = 16) using a stratiﬁcation
based on median daily cigarette consumption (10–19 and 20–30
cigarettes per day [CPD]). On randomization, subjects continuing
to smoke Lark1 were ‘blind’ to the identity of the test cigarette.
Non-randomized subjects were released from the study center
after completion of all scheduled assessments. Subjects withdraw-
ing from the study or those removed by the investigator afterEHCSS-K3 (N = 28) 
rolled smoking (9 days) 
No smoking (N = 16) 
Days 1 to 8 
essments (blood and 24-h urine) 
Lark1 (N = 28) 
Lark1 cigarette prior to randomization into the three study groups. All cigarettes
Table 1
Summary of smoke constituent biomarkers, and bioanalytical methods.
Smoke constituent Biomarker Matrix Analytical methoda Lower limit of quantiﬁcation
1,3-Butadiene Monohydroxybutenyl mercapturic acid (MHBMA) Urine LC–MS/MS 100 pg/ml
2-Naphthylamine 2-Naphthylamine (2-NA) Urine GC–MS 5.0 pg/ml
4-Aminobiphenyl 4-Aminobiphenyl (4-ABP) Urine GC–MS 5.0 pg/ml
Acrolein 3-Hydroxypropyl mercapturic acid (3-HPMA) Urine LC–MS/MS 35 ng/ml
Acrylamide Acrylamide mercapturic acid (AAMA) Urine LC–MS/MS 2.5 ng/ml
Glycidamide mercapturic acid (GAMA) LC–MS/MS 1.5 ng/ml
Benzene S-Phenyl mercapturic acid (S-PMA) Urine LC–MS/MS 20 pg/ml
CO Carboxyhemoglobin (COHb) Blood Spectrophotometry 0.3% saturation
Crotonaldehyde 3-Hydroxy-1-methylpropyl mercapturic acid (3-HMPMA) Urine LC–MS/MS 92 pg/ml
Nicotine Cotinine (COT-P) Plasma LC–MS/MS 1.0 ng/ml
Nicotine (NIC-P) Plasma LC–MS/MS 1.0 ng/ml
Nicotine equivalents (NEq)c Urine LC–MS/MS NAf
NNKb Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)d Urine LC–MS/MS 5.0 pg/ml
Pyrene Total 1-hydroxypyrene (1-OHP)e Urine LC–MS/MS 10 pg/ml
o-Toluidine o-Toluidine (o-TOL) Urine GC–MS 25 pg/ml
Mutagens Salmonella mutagenicity (YG1024 with S9) Urine Ames plate incorporation assay NA
a Analytical methods abbreviated as: LC–MS/MS, liquid chromatography-tandem mass spectrometry; and GC–MS, gas chromatography-mass spectrometry.
b NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
c Nicotine equivalents (NEq) were determined as the molar sum of nicotine, cotinine, and trans-3’-hydroxycotinine plus their respective glucuronide conjugates.
d Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) was determined as the molar sum of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its O-glucuronide
conjugate.
e Total 1-hydroxypyrene (1-OHP) was determined as the molar sum of 1-hydroxypyrene and its glucuronide and sulfate conjugates.
f NA, not applicable.
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participated in their assigned study groups. Assessments included
determination of biomarkers of exposure in 24-h urine samples
(starting at 07:00), vital signs (07:00), COHb07:00, COT-P17:00, and
NIC-P17:00. On Day 9 (end of study), vital signs, ECG, clinical labora-
tory, and a physical examination were performed at 07:00 prior to
release of subjects from the study center.
On Day -2 and Day -1, subjects were only permitted to smoke
Lark1 cigarettes. From Day 1 through Day 8 subjects smoked their
randomized study cigarettes. Lark1 cigarettes were lit using a blue
ﬂame gas lighter. EHCSS-K3 cigarettes were smoked using the
EHCSS series-K heater (Werley et al., 2008). To ensure study integ-
rity, all Lark1 cigarette butts and smoked EHCSS-K3 cigarettes were
collected. During the in-clinic study period smoking was permitted
only at designated smoking times from 07:30 to 23:00 and subjects
were never encouraged to smoke at any time during the study. All
subjects received a dietician-designed low-mutagen diet (Smith
et al., 1996) and water was allowed ad libitum. Identical menus
were served on Days -2, 4, and 7 (days preceding determination
of urinary mutagenicity), and on Days -1, 5, and 8 (days on which
urinary mutagenicity was determined).
The study was conducted at the Clinical Trial Center, Seoul Na-
tional University Hospital, Korea, and was conducted in compli-
ance with the ethical principles that have their origin in the
Declaration of Helsinki and that are consistent with Good Clinical
Practice (1964, and regularly amended; 1996) and the Korean
Guidelines for Good Clinical Practice (Korean Food and Drug
Administration, 2006). The study was approved by the Institutional
Review Board of the Seoul National University Hospital.
2.4. Bioanalytical methodology
All urine voided in a 24-h period on study Days -1 through Day
8 was stored refrigerated at 2–8 C on the day of urine collection.
Total urine volume was measured, and aliquots were stored frozen
at 20 C pending biomarker analysis (Table 1). Both tobacco-spe-
ciﬁc and tobacco-related biomarkers of exposure to HPHC were
determined (Hecht, 2003; Lindner et al., 2011; Schorp et al.,
2012): (i) tobacco-speciﬁc biomarkers of exposure were deter-
mined for nicotine (Benowitz et al., 1994) and NNK (Carmella
et al., 2003), and (ii) tobacco-related biomarkers of exposure wereselected for 1,3-butadiene (van Sittert et al., 2000), 2-naphthyl-
amine (Riedel et al., 2006), 4-aminobiphenyl (Riedel et al., 2006),
acrolein (Mascher et al., 2001), acrylamide (Urban et al., 2006),
benzene (Medeiros et al., 1997), crotonaldehyde (Scherer et al.,
2007), pyrene (Strickland et al., 1996), and o-toluidine (Riedel
et al., 2006). All biomarkers were determined by liquid chromatog-
raphy–tandem mass spectrometry (LC–MS/MS) or gas chromatog-
raphy–mass spectrometry (GC–MS) using methods validated
according to US Food and Drug Administration (FDA) Guidance
(Food and Drug Administration, 2001). Some of the instrumenta-
tion used (Table 1) differs to that reported in the original methods.
Excretion of mutagenic material in urine towards Salmonella
typhimurium YG1024 was determined using the Ames plate incor-
poration assay (Einistö et al., 1990). Blood samples for determina-
tion of COHb (Pojer et al., 1984) were drawn in sodium heparin
vacutainer tubes and measured on the day of collection by spectro-
photometry. Blood samples for determination of COT-P and NIC-P
were drawn in sodium heparin vacutainer tubes and plasma stored
at 20 C prior to analysis by LC–MS/MS (Benowitz, 1988).
All laboratory analyses were performed in a blinded manner
without knowledge of the study group assignment.
2.5. Data analysis
For data summary and statistical analysis, biomarker values be-
low the lower limit of quantiﬁcation (LLOQ) were set to LLOQ/2.
Exposure to nicotine was analysed based on nicotine equivalents
(NEq) excretion, calculated as the molar sum of the concentrations
of nicotine and the ﬁve major nicotine metabolites (nicotine-glu-
curonide, free cotinine, cotinine-glucuronide, free trans-30-
hydroxycotinine, and trans-30-hydroxycotinine-glucuronide) in ur-
ine. Urine samples showing signs of cytotoxicity and/or precipitate
were excluded from the mutagenicity analysis.
Descriptive statistics were derived for each biomarker by study
group and day. Baseline comparability of different study groups
was examined using the non-parametric Kruskal–Wallis test.
Changes in biomarker values (from baseline to Day 8) within each
study group were analyzed by paired sample t-tests (two-sided,
a = 0.05).
Differences at Day 8 between EHCSS-K3 and Lark1 were ana-
lyzed by analysis of covariance (ANCOVA) with factors study group,
Table 2
Demographic summary by study group.
Variable and statistics Study groupa
Lark1 EHCSS-K3 No-smoking
Number (N) 28 28 16
Age (mean ± SD) 24.1 ± 4.1 23.7 ± 2.2 23.4 ± 3.4
Gender (N, % of total)
Female 9 (32.1%) 5 (17.9%) 4 (25.0%)
Male 19 (67.9%) 23 (82.1%) 12 (75.0%)
BMIb (kg/m2, mean ± SD) 22.3 ± 1.9 22.6 ± 2.0 22.3 ± 1.8
Duration of smoking
(N years, % of total)
3 Years or less 0 (0.0%) 6 (21.4%) 5 (31.3%)
4–9 Years 22 (78.6%) 20 (71.4%) 8 (50.0%)
10–15 Years 5 (17.9%) 2 (7.1%) 3 (18.8%)
16–19 Years 0 (0.0%) 0 (0.0%) 0 (0.0%)
20–25 Years 1 (3.6%) 0 (0.0%) 0 (0.0%)
More than 25 years 0 (0.0%) 0 (0.0%) 0 (0.0%)
Fagerström Scorec (mean ± SD) 4.1 ± 1.9 3.7 ± 1.8 3.1 ± 1.5
a Groups abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 non-
menthol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); Lark1, Lark One non-
menthol cigarette (1 mg tar, 0.1 mg nicotine, and 1.5 mg CO); and No-smoking,
smoking cessation group.
b BMI, body mass index;
c The Fagerström Score was calculated as published Heatherton et al. (1991).
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baseline as covariate. Interaction terms for study group  gender
and study group  daily cigarette consumption were included into
the model if signiﬁcant interactions (at the a = 0.1 level) were evi-
dent. If the global test showed a signiﬁcant difference between
study groups (at the a = 0.05 level), pairwise comparisons of
EHCSS-K3 and Lark1 were performed according to Dunnett (one-
sided at a = 0.025).
Changes in urinary mutagenicity were analyzed using square
root-transformed data since the data was not normally distributed.
Descriptive statistics were also derived by study group for NEq
after adjustment by the individual number of cigarettes smoked
per day (NEqNCig). All urinary biomarkers were also compared after
adjustment for creatinine excretion. Due to the high frequency of
concentration values below the LLOQ determined for 2-naphthyl-
amine and 4-aminobiphenyl in all study groups on all study days,
nonparametric statistics were used to determine changes from
Day-1 to Day 8 using the Wilcoxon Signed Rank test.
All statistical analyses were of an exploratory nature. Therefore,
apart from adjustment for the pairwise comparisons of biomarker
level, no further adjustment for multiplicity was performed.
All statistical analyses were performed using SAS Version 8.2.
Unless otherwise stated, all analyses are reported for the intent-to-
treat population (ITT) which included all subjects who had a valid
assessment of the primary biomarker variables at baseline and at
least one post-baseline assessment (subjects in the two smoking
groups must have smoked at least one study cigarette).
2.6. Determination of sample size
It was assumed that Lark1 smokers would have a comparable
concentration of COHb at 17:00 (COHb17:00) to that seen in a pre-
vious unpublished study in Japan. In this study, subjects who
smoked Lark1 cigarettes for 8 days had an average concentration
of 3.63 ± 1.85% COHb17:00 on Day 8. It was also assumed that the
COHb17:00 concentration in the EHCSS-K3 group would be at least
40% lower. For a two-sample t-test of a mean difference (pairwise
comparison of EHCSS-K3 with Lark1) with a normal one-sided sig-
niﬁcance level of a = 0.05 and assuming a common standard devi-
ation of r = 1.8, a sample size of 28 subjects per group was
required to obtain a test power of at least 90% (1  b = 0.9) to de-
tect a 40% difference in mean COHb17:00 concentrations between
the EHCSS-K3 group (2.18%) and the Lark1 group (3.63%). A size
of 28 subjects in each smoking group was retained in the study
for practical reasons. A no-smoking group was included to show
the maximal reduction in COHb17:00 on smoking cessation. A size
of 16 subjects in the no-smoking group was chosen based on prac-
tical reasons.
2.7. Adverse events, medical history, and concomitant medication
Adverse events (AEs) and medical history were coded using the
Medical Dictionary for Regulatory Activities (MedDRA, Version
8.1). Medication was coded according to the World Health Organi-
zation (WHO) Drug Reference List (WHO, 2005 quarter 1).3. Results
3.1. Demographic and other baseline characteristics
The ITT population consisted of 72 subjects of Korean origin.
Demographic characteristics by study group are summarized in
Table 2. Overall, the male/female proportion was 3:1 (54 males
and 18 females) with slightly different ratio in the EHCSS-K3 and
Lark1 groups. The mean subject age was 23.8 ± 3.3 years (range:20–42 years) and mean body mass index (BMI) was 22.3 ± 1.9 kg/
m2 (range: 18.8–27.0 kg/m2). There were no signiﬁcant differences
between males and females with respect to age, BMI, and duration
of smoking in the different study groups. The majority of females
(88.9%) and about half of males (46.3%) reported to smoke 10–19
CPD. The majority of subjects (84.7%) had a smoking history of less
than 10 years. There was no signiﬁcant difference between the
FTND score between male (mean score: 3.8 ± 1.6 [mean ± standard
deviation]) and female (mean score: 3.3 ± 2.0) subjects. FTND
scores were lower for smokers of 10–19 CPD (mean score:
3.3 ± 2.0) compared to smokers of 20–30 CPD (mean score:
4.2 ± 1.5).
Clinical and laboratory assessments at baseline revealed several
minor deviations outside the normal range of values in the ran-
domized subjects. However, all deviations were judged to be clin-
ically insigniﬁcant. After randomization, all subjects completed the
study.
3.2. Cigarette consumption
The mean number of CPD for both smoking groups increased
slightly from Day -1 (baseline) to Day 8 (Table 3). On Day 1, the
ﬁrst day when subjects smoked their respective randomized study
cigarette, the mean number of cigarettes smoked was increased in
both smoking groups. On Day 8, the average cigarette consumption
in both groups was comparable, although higher than at baseline.
3.3. Biomarkers of exposure
There were no statistically signiﬁcant group differences in
COHb17:00 and biomarkers of exposure to 1,3-butadiene, crotonal-
dehyde, nicotine, o-toluidine, pyrene, and excretion of mutagenic
material in 24-h urine at baseline (Table 4). However, a global
group difference at baseline was evident for AAMA, a biomarker
of exposure to acrylamide (Kruskal–Wallis test p < 0.05).
Exposure to CO, assessed as either COHb17:00 (the primary
objective of the study) or daytime change in COHb saturation
(DCOHb17:00-07:00), was signiﬁcantly decreased (p < 0.05) in the
EHCSS-K3 and no-smoking groups at Day 8, compared to baseline.
A statistically signiﬁcant increase (p < 0.05) in COHb17:00 (but not
in DCOHb17:00-07:00) was evident in the Lark1 group at Day 8, com-
Table 3
Daily cigarette consumption by group and study day (mean ± SD).
Study daya Study groupb
Lark1 (N = 28) EHCSS-K3 (N = 28) No-smoking (N = 16)
Day-1 (Baseline) 15.0 ± 4.3 14.6 ± 3.1 13.7 ± 3.3
Day 1 15.8 ± 4.4 16.9 ± 4.0 0
Day 2 15.6 ± 4.5 16.8 ± 3.5 0
Day 3 15.8 ± 4.4 17.1 ± 4.3 0
Day 4 16.1 ± 4.6 17.2 ± 4.4 0
Day 5 16.0 ± 4.6 17.6 ± 4.2 0
Day 6 16.2 ± 4.3 17.6 ± 4.2 0
Day 7 16.0 ± 4.4 17.4 ± 4.2 0
Day 8 16.4 ± 4.1 17.8 ± 4.5 0
a At Day 0 (baseline) all groups smoked the Lark1 cigarette. On Day 1 through Day
8 groups smoked their randomized study cigarette or stopped smoking.
b Groups abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 non-
menthol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); Lark1, Lark One non-
menthol cigarette (1 mg tar, 0.1 mg nicotine, and 1.5 mg CO); and No-smoking,
smoking cessation group.
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naphthylamine, 4-aminobiphenyl, acrylamide (AAMA only), ben-
zene, nicotine (determined as NEq, COT-P17:00, and NIC-P17:00),
NNK, pyrene, and o-toluidine, as well as excretion of mutagenic
material in urine were statistically signiﬁcantly decreased
(p < 0.05) in the EHCSS-K3 and no-smoking groups at Day 8, com-
pared to baseline (Table 4). No signiﬁcant change was observed in
exposure to acrolein and crotonaldehyde in the EHCSS-K3 group at
Day 8, compared to baseline. In the no-smoking group, exposure to
acrolein was signiﬁcantly decreased (p < 0.05) while exposure to
crotonaldehyde was unchanged at Day 8, compared to baseline.
In the Lark1 group, statistically signiﬁcant increases (p < 0.05) in
biomarkers of exposure to 1,3-butadiene, 2-naphthylamine, ben-
zene, nicotine (determined as NEq and COT-P17:00), and NNK, as
well as excretion of mutagenic material in urine were evident at
Day 8, compared to baseline. No signiﬁcant changes were observed
for biomarkers of exposure to 4-aminobiphenyl, acrolein, acrylam-
ide, pyrene, and o-toluidine, while exposure to crotonaldehyde was
markedly increased at Day 8, compared to baseline. The trends did
not change after adjustment for the number of cigarettes smoked
during the sampling period or adjustment for urinary creatinine
excretion.
Nearly all comparisons by ANCOVA indicated statistically sig-
niﬁcant differences in biomarkers of exposure (all p < 0.001) on
Day 8 between the EHCSS-K3 and Lark1 groups, with the EHCSS-
K3 group having lower levels of all biomarkers. The only excep-
tions were biomarkers used to assess exposure to acrolein and cro-
tonaldehyde (Table 5). Nonparametric statistics using the Mann–
Whitney U-test showed statistically signiﬁcant differences (both
p < 0.001) for exposure to 2-naphthylamine and 4-aminobiphenyl.3.4. Safety evaluations
Five subjects (6.9%) reported at least one AE (6 AE episodes in
total) after randomization on Day 1. Overall, there were no trends
related to the study groups observed in the AE reports, clinical lab-
oratory, ECG, and physical examinations. The most commonly re-
ported AE was eye disorders (Lark1: one subject; no-smoking:
one subject on two occasions). All reported AEs were of mild inten-
sity, and all were judged to be unrelated to the study cigarettes or
study procedures. A general tendency to slightly decreased systolic
and diastolic blood pressure was observed in the EHCSS-K3 and
Lark1 groups, while there were no relevant changes in the no-
smoking group. There were no withdrawals due to an AE and no
occurrence of a serious adverse event.4. Discussion
The reported study of adult smokers in a controlled clinical
environment was conducted to evaluate changes in selected bio-
markers of exposure to cigarette smoke HPHC occurring after con-
trolled ‘switching’ from a conventional lit-end low-tar cigarette
(Lark1) to the EHCSS-K3, or to no-smoking. A randomized, con-
trolled, open-label, parallel group study design was used to mini-
mize bias and variability. Since it was unlikely that a single
biomarker could provide an assessment of exposure to multiple
HPHC present in cigarette smoke (Shields, 2002), a series of bio-
markers of exposure to different gas–vapor and particulate phase
of cigarette smoke HPHC were investigated (Table 1). Cigarette
smoke HPHC were selected based on the availability of validated
methods of analysis for the respective biomarkers of exposure.
Controlled ‘switching’ was used to maintain a fairly constant num-
ber of cigarettes smoked per day (Table 3) and to minimize the ef-
fects of compensation on switching to smoking a cigarette of
different tar (and/or nicotine) yield (Scherer, 1999). After random-
ization, subjects who continued to smoke the Lark1 cigarette in-
creased the number of cigarettes smoked per day by about 10%
compared to an increase of about 20% in smokers who switched
to the EHCSS-K3 cigarette, a cigarette of higher tar and nicotine
delivery (Table 3).
A statistically signiﬁcant mean reduction (p < 0.05) in
COHb17:00, the primary endpoint of the study, was observed in
the EHCSS-K3 group at Day 8, compared to baseline (Fig. 2; Table 4).
This reduction was conﬁrmed by determination of a signiﬁcant
mean reduction (p < 0.05) in DCOHb17:00-07:00 (Table 4) suggesting
that exposure to CO in smokers of EHCSS-K3 cigarettes was re-
duced by about 75%. By comparison, a statistically signiﬁcant mean
increase (p < 0.05) in COHb17:00 and a non-signiﬁcant increase in
DCOHb17:00-07:00 was observed in the Lark1 group (17.6% and
73.0%, respectively), while statistically signiﬁcant mean reductions
(p < 0.05) in COHb17:00 and DCOHb17:00-07:00 occurred in the no-
smoking group (83.5% and 98.5%, respectively). Other studies have
reported a signiﬁcant reduction in exposure to CO in smokers who
switch from conventional lit-end non-menthol cigarettes to using
previous generations of the EHCSS heater and smoking the EHCSS
non-menthol cigarette (Buchhalter and Eissenberg, 2000; Buchhal-
ter et al., 2001; Hughes and Keely, 2004; Roethig et al., 2005, 2007)
and to using the current third-generation EHCSS series-K heater
and smoking the EHCSS-K3 non-menthol cigarette (Frost-Pineda
et al., 2008a,b; Tricker et al., 2012a,b). Similar reductions in expo-
sure to CO are evident in smokers who switch from smoking the
Marlboro Ultra Lights Menthol cigarette to smoking the EHCSS ser-
ies-K menthol cigarette (Tricker et al., 2012c). However, contrary
to these studies in which exposure to CO and various additional
cigarette smoke HPHC were assessed on switching from a conven-
tional lit-end cigarette of identical or higher tar/nicotine yield to
using an EHCSS heater and EHCSS cigarette of identical or lower
tar/nicotine yield, this study reports that exposure to CO and other
cigarette smoke HPHC is also signiﬁcantly reduced after switching
to use of an EHCSS heater and EHCSS cigarette of higher tar/nico-
tine yield.
Tobacco-speciﬁc biomarkers of exposure to nicotine (NEq,
COT-P17:00, and NIC-P17:00) (Tricker, 2006) and the tobacco-speciﬁc
N-nitrosamine NNK (total NNAL) (Hecht and Tricker, 1999) were
statistically signiﬁcantly reduced (p < 0.05) in the EHCSS-K3 and
no-smoking groups at Day 8, compared to baseline (Table 4). The
signiﬁcant reductions (p < 0.05) in exposure to nicotine deter-
mined as NEq and COT-P17:00 (40.3% and 44.7%, respectively) in
the EHCSS-K3 group on Day 8, compared to baseline, are notable
since the EHCSS-K3 cigarette has a higher smoke nicotine yield
and 20% more EHCSS-K3 cigarettes were smoked than at baseline
Table 4
Mean absolute biomarker levels and percentage change from Day -1 (baseline) to Day 8 per study group.
Smoke constituent biomarkera,b Study groupc
Lark1 (N = 28) EHCSS-K3 (N = 28) NS (N = 16)
COHb17:00 (%)
§
Day -1 3.73 ± 1.46 3.68 ± 1.16 3.54 ± 1.50
Day 8 4.19 ± 1.74 0.93 ± 0.39 0.48 ± 0.23
Percentage change 17.6 ± 38.1%* 74.2 ± 10.1%* 83.5 ± 12.6%*
DCOHb17:00–07:00 (%)
Day -1 1.60 ± 1.10 1.29 ± 0.77 1.44 ± 0.92
Day 8 2.07 ± 1.24 0.22 ± 0.41 0.06 ± 0.38
Percentage change 73.0 ± 116.6% 75.0 ± 90.7%* 98.5 ± 56.0%*
NEq (mg/24 h)
Day -1 8.11 ± 3.45 7.34 ± 3.01 6.45 ± 3.00
Day 8 8.93 ± 3.65 4.22 ± 2.53 0.06 ± 0.02
Percentage change 14.2 ± 25.9%* 40.3 ± 29.5%* 98.9 ± 0.6%*
COT-P17:00 (ng/ml)
Day -1 156.22 ± 67.64 155.61 ± 82.01 144.01 ± 76.98
Day 8 180.11 ± 76.32 85.78 ± 57.54 5.00 ± 0.00
Percentage change 15.8 ± 25.1%* 44.7 ± 25.0%* 93.8 ± 6.6%*
NIC-P17:00 (ng/ml)
Day -1 11.65 ± 8.58 13.30 ± 7.16 11.04 ± 5.02
Day 8 14.04 ± 6.90 8.64 ± 5.06 0.05 ± 0.00
Percentage change 64.7 ± 98.3% 20.0 ± 66.4%* 93.9 ± 4.8%*
MHBMA (lg/24 h)
Day -1 1.90 ± 2.22 1.53 ± 1.88 1.63 ± 1.40
Day 8 2.32 ± 2.67 0.59 ± 0.58 0.28 ± 0.27
Percentage change 22.7 ± 38.0%* 32.4 ± 67.5%* 63.1 ± 45.6%*
2-NA (ng/24 h)
Day -1: Median (Q25, Q75) 31.3 (20.2, 50.7) 34.6 (22.5, 54.8) 33.5 (11.0, 46.6)
Day 8. Median (Q25, Q75) 46.3 (27.5, 53.8) 5.4 (4.6, 6.4) 5.5 (4.8, 7.0)
Absolute change: Median (Q25, Q75) 7.8 (1.1, 7.8) 29.1 (49.5, 15.9) 27.1 (41.9, 4.9)
4-ABP (ng/24 h)
Day -1: Median (Q25, Q75) 10.3 (5.6, 17.8) 8.1 (5.2, 15.9) 11.4 (7.1, 14.6)
Day 8: Median (Q25, Q75) 12.1 (6.5, 18.0) 5.5 (4.7, 6.6) 5.5 (4.8, 7.0)
Absolute change: Median (Q25, Q75) 0.4 (1.0, 5.5) 1.5 (9.9, 0.1) 4.9 (0.5, 1.0)
3-HPMA (mg/24 h)
Day -1 3.01 ± 1.20 2.57 ± 0.75 2.61 ± 0.73
Day 8 2.94 ± 0.84 2.41 ± 0.67 1.68 ± 0.37
Percentage change 1.5 ± 20.1% 1.3 ± 35.8% 32.5 ± 17.0%*
AAMA (lg/24 h)
Day -1 246.33 ± 76.94 205.55 ± 77.67 188.01 ± 51.90
Day 8 255.55 ± 66.31 162.70 ± 45.08 147.77 ± 27.38
Percentage change 7.8 ± 21.5% 15.0 ± 22.3%* 17.9 ± 19.2%*
GAMA (lg/24 h)
Day -1 16.71 ± 5.84 15.22 ± 5.24 14.98 ± 5.58
Day 8 16.50 ± 4.87 12.90 ± 4.08 11.66 ± 2.44
Percentage change 2.7 ± 21.5% 9.9 ± 28.0% 17.4 ± 19.1%*
S-PMA (lg/24 h)
Day -1 3.78 ± 2.17 3.23 ± 1.78 3.41 ± 1.88
Day 8 4.86 ± 3.38 1.63 ± 0.55 1.37 ± 0.42
Percentage change 28.7 ± 39.9%* 40.1 ± 27.2%* 46.3 ± 37.3%*
3-HMPMA (mg/24 h)
Day -1 2.04 ± 0.91 2.13 ± 1.01 1.96 ± 0.94
Day 8 2.42 ± 0.87 1.99 ± 1.07 1.66 ± 0.60
Percentage change 40.2 ± 74.6% 28.1 ± 155.3% 3.4 ± 41.8%
Total NNAL (ng/24 h)
Day -1 174.59 ± 100.35 161.81 ± 110.48 146.34 ± 86.08
Day 8 198.52 ± 108.89 80.43 ± 59.31 45.06 ± 37.82
Percentage change 20.9 ± 33.4* 50.5 ± 14.5* 71.6 ± 14.7%*
Total 1-OHP (ng/24 h)
Day -1 247.28 ± 57.66 236.45 ± 66.63 236.02 ± 68.18
Day 8 238.46 ± 55.72 143.62 ± 76.08 127.04 ± 24.71
Percentage change 1.1 ± 26.1% 38.2 ± 24.4%* 43.1 ± 16.2%*
o-TOL (ng/24 h)
Day -1 82.73 ± 26.59 84.33 ± 30.54 70.53 ± 29.64
Day 8 85.86 ± 27.34 29.12 ± 13.32 30.20 ± 8.35
Percentage change 10.0 ± 41.1% 61.8 ± 20.3%* 47.5 ± 28.2%*
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Table 4 (continued)
Smoke constituent biomarkera,b Study groupc
Lark1 (N = 28) EHCSS-K3 (N = 28) NS (N = 16)
Mutagenicity (rev/24 h)d
Day -1 18823 ± 9402 19105 ± 8227 17139 ± 6258
Day 8 22991 ± 11402 11218 ± 5419 8420 ± 3681
Percentage change 31.5 ± 50.3* 31.8 ± 48.8%* 45.3 ± 29.7%*
a Smoke constituent biomarkers abbreviated as: 1-OHP, 1-hydroxypyrene; 2-NA, 2-naphthylamine; 3-HMPMA, 3-hydroxy-1-methylpropyl mercapturic acid; 3-HMPMA, 3-
hydroxy-1-methylpropyl mercapturic acid; 3-HPMA, 3-hydroxypropyl mercapturic acid; 4-ABP, 4-aminobiphenyl; AAMA, acrylamide mercapturic acid; COHb17:00, car-
boxyhemoglobin at 17:00; DCOHb17:00-07:00, daytime increase in COHb from 07:00 to 17:00; COT-P17:00, plasma cotinine at 17:00; GAMA, glycidamide mercapturic acid;
MHBMA, monohydroxybutenyl mercapturic acid; NEq, nicotine equivalents; NIC-P17:00, plasma nicotine at 17:00; NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; S-
PMA, S-phenyl mercapturic acid; and o-TOL, o-toluidine.
b At Day 0 (baseline) all groups smoked the Lark1 cigarette. On Day 1 through Day 8 groups smoked their randomized study cigarette or stopped smoking.
c Groups abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 non-menthol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); Lark1, Lark One non-menthol
cigarette (1 mg tar, 0.1 mg nicotine, and 1.5 mg CO); and No-smoking, smoking cessation group.
d Rev, revertants.
§ Primary objective.
* Signiﬁcant change within group from Day 0 to Day 8 (p < 0.05, p-value from two-sided paired sample t-test).
 Signiﬁcant change within group from Day -1 to Day 8 (p < 0.05 from Wilcoxon Signed Rank test).
Table 5
Comparison between study cigarettes by ANCOVA (baseline-adjustedmeans on Day 8).
Smoke constituent biomarkera Comparisonbc
EHCSS-K3 vs. Lark1
COHb17:00 (%)§ 3.24 (0.23)⁄⁄⁄
DCOHb17:00–07:00 (%) 1.69 (0.21)⁄⁄⁄
NEq (mg/24 h) 4.52 (0.55)⁄⁄⁄
COT-P17:00 (ng/ml) 99.72 (10.16)⁄⁄⁄
NIC-P17:00 (ng/ml) 6.26 (1.36)⁄⁄⁄
MHBMA (lg/24 h) 1.41 (0.29)⁄⁄⁄
2-NA (ng/24 h) 463.00⁄⁄⁄
4-ABP (ng/24 h) 592.50⁄⁄⁄
3-HPMA (mg/24 h) 0.25 (0.17)
AAMA (lg/24 h) 91.42 (13.41)⁄⁄⁄
GAMA (lg/24 h) 3.09 (0.95)⁄⁄
S-PMA (lg/24 h) 2.68 (0.55)⁄⁄⁄
3-HMPMA (mg/24 h) 0.43 (0.27)
Total NNAL (ng/24 h) 111.79 (12.80)⁄⁄⁄
Total 1-OHP (ng/24 h) .54.01 (15.57)⁄⁄⁄
o-TOL (ng/24 h) 56.70 (5.09)⁄⁄⁄
Mutagenicity (rev/24 h)d 11483.2 (1939.83)⁄⁄⁄
a Smoke constituent biomarkers abbreviated as: 1-OHP, 1-hydroxypyrene; 2-NA,
2-naphthylamine; 3-HMPMA, 3-hydroxy-1-methylpropyl mercapturic acid; 3-
HMPMA, 3-hydroxy-1-methylpropyl mercapturic acid; 3-HPMA, 3-hydroxypropyl
mercapturic acid; 4-ABP, 4-aminobiphenyl; AAMA, acrylamide mercapturic acid;
COHb17:00, carboxyhemoglobin at 17:00; DCOHb17:00-07:00, daytime increase in
COHb from 07:00 to 17:00; COT-P17:00, plasma cotinine at 17:00; GAMA, glycida-
mide mercapturic acid; MHBMA, monohydroxybutenyl mercapturic acid; NEq,
nicotine equivalents; NIC-P17:00, plasma nicotine at 17:00; NNAL, 4-(methylnit-
rosamino)-1-(3-pyridyl)-1-butanol; S-PMA, S-phenyl mercapturic acid; and o-TOL,
o-toluidine.
b Groups abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 non-
menthol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); and Lark1, Lark One
non-menthol cigarette (1 mg tar, 0.1 mg nicotine, and 1.5 mg CO).
c Least squares mean (SE) and Bonferoni-corrected p-value according to Dunnett:
⁄, p < 0.05; ⁄⁄, p < 0.01; ⁄⁄⁄, p < 0.001.
d Rev, revertants.
§ Primary objective.
 Nonparametric analysis using the Mann–Whitney U-test.
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number of cigarettes smoked (approximately 10%) by subjects
who continued to smoke the Lark1 cigarette (Table 3), statistically
signiﬁcant mean increases (p < 0.05) were observed for both NEq
and COT-P17:00 (14.2% and 15.8%, respectively).
Signiﬁcant mean reductions (p < 0.05) in exposure to 1,3-buta-
diene, 2-naphthylamine, 4-aminobiphenyl, benzene, pyrene, and
o-toluidine were also observed in the EHCSS-K3 and no-smoking
groups at Day 8, compared to baseline (Table 4). The reduction in
exposure to acrylamide in the no-smoking group was apparentusing two different biomarkers of exposure; however, only one
biomarker of exposure (AAMA) suggested that a statistically signif-
icant reduction in exposure to acrylamide also occurred in the
EHCSS-K3 group.
A signiﬁcant mean reduction (p < 0.05) in exposure to acrolein
was observed in the no-smoking group, but not in the EHCSS-K3
group. In the Lark1 group, statistically signiﬁcant increases
(p < 0.05) were observed for biomarkers of exposure to 1,3-butadi-
ene, 2-naphthylamine, benzene, nicotine (determined as NEq and
COT-P17:00), and NNK at Day 8, compared to baseline. No signiﬁcant
change was observed for exposure to 4-aminobiphenyl, acrolein,
acrylamide, pyrene, and o-toluidine. There were no statistically
signiﬁcant changes in exposure to crotonaldehyde in any of the
three groups.
Statistically signiﬁcant reductions (p < 0.05) in excretion of
mutagenic material in urine were observed in the EHCSS-K3 and
no-smoking groups at Day 8, compared to baseline (Table 4). Sim-
ilar observations have been reported in previous studies under in-
clinic conﬁnement conditions evaluating earlier generations of the
EHCSS heater and EHCSS cigarettes (Roethig et al., 2005, 2007) and
the current third-generation EHCSSS heater using EHCSS series-K
cigarettes (Frost-Pineda et al., 2008a; Tricker et al., 2012a,b,c). By
comparison, a statistically signiﬁcant increase (p < 0.05) in excre-
tion of mutagenic material in urine was observed in the Lark1
group at Day 8, compared to baseline. Salmonella typhimurium
YG1024, an O-acetyltransferase-overproducing derivative of tester
strain TA98, is sensitive to the mutagenic activity of aromatic ami-
no, hydroxylamino, and nitro compounds present in urine (Einistö
et al., 1990). Although the mainstream cigarette smoke HPHC
responsible for excretion of mutagenic material are unknown, bio-
markers of exposure to both 2-naphthylamine and 4-aminobi-
phenyl were also signiﬁcantly increased (p < 0.05) in the EHCSS-
K3 group at Day 8, compared to baseline.
In pair-wise comparisons of Lark1 and EHCSS-K3 cigarettes (Ta-
ble 5), signiﬁcant reductions (p 6 0.01) in all biomarkers of expo-
sure, except for those used to determine exposure to acrolein
and crotonaldehyde, were found in the EHCSS-K3 group. The latter
may be due to the unspeciﬁc nature of the corresponding biomark-
ers to detect small differences in tobacco-related exposure (Hecht
et al., 2001; Stevens and Maier, 2008).
It should be noted that there are some limitations to the present
study (Schorp et al., 2012). In particular, the short-term conﬁne-
ment used in the study and the number of cigarettes smoked by
each subject. Despite these limitations, signiﬁcant changes in most
of the biomarkers of exposure were observed (Table 4). However,
for most subjects, the majority of concentrations for 4-aminobi-
Fig. 2. Carboxyhemoglobin (% saturation at 17:00) by group and study day (mean ± SD).
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randomization, and some doubt exists as to the speciﬁcity of bio-
markers of exposure to acrolein (Stevens and Maier, 2008) and cro-
tonaldehyde (Hecht et al., 2001). The results of this study provide a
clear indication of exposure reduction in smokers who use the
EHCSS series-K heater and smoke the EHCSS-K3 cigarette under
controlled clinical conditions; however, caution needs to be taken
before attempting to extrapolate results from this short-term study
performed in a controlled clinical environment to the long-term ef-
fects of switching to an EHCSS under real-life conditions (Frost-
Pineda et al., 2008b; Martin Leroy et al., 2012).
In summary, the current study shows mean reductions in bio-
markers of exposure to 10 of 12 selected cigarette smoke HPHC
(1,3-butadiene, 2-naphthylamine, 4-aminobiphenyl, acrylamide,
benzene, CO, nicotine, NNK, pyrene, and o-toluidine) from baseline
to Day 8 in Lark1 smokers who switch to smoke EHCSS-K3 ciga-
rettes (1.3 ± 35.8% to 74.2 ± 10.1%). No change was determined
for biomarkers of exposure to crotonaldehyde and acrolein, but
some doubt exists as to the speciﬁcity of the applied biomarkers
of exposure. In smokers who continued to smoke the Lark1 ciga-
rette, exposure to the majority of cigarette smoke HPHC (1,3-buta-
diene, 2-naphthylamine, 4-aminobiphenyl, acrylamide, benzene,
CO, crotonaldehyde, nicotine, NNK, and o-toluidine) increased,
while exposure to acrolein and pyrene were decreased. With the
exception of 1,3-butadiene, 2-naphthylamine, benzene, CO, nico-
tine, and NNK, few of the changes reached the level of statistical
signiﬁcance. The largest mean reductions in all cigarette smoke
HPHC occurred in smokers who switched to no-smoking
(3.4 ± 41.8% to 98.9 ± 0.6%). Excretion of mutagenic material
in urine was signiﬁcantly decreased (p < 0.05) in the EHCSS-K3
and no-smoking groups (31.8 ± 48.8% and 45.3 ± 29.7%, respec-
tively), and signiﬁcantly increased (p < 0.05) in the Lark1 group
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